A home-based healthcare provider raises the low end of its 2026 revenue forecast to $316 million.

Viemed Healthcare (VMD) reported Q3 2026 revenue of $80.7M, up 12.2% YoY, and raised its 2026 revenue forecast low end to $316M. Net income rose 32% YoY to $4.6M, with adjusted EBITDA at $17.1M. The company also updated its full-year guidance, narrowing Adjusted EBITDA and lowering net capital expenditure outlook.

Original reporting
Published Nov 4, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$VMD
Bullish
high confidence
Mentioned
$VMD
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$VMDBullishHigh
01

Why it matters

The upward revision of revenue guidance and record quarterly performance are likely to attract investor interest and could drive the stock higher in the near term.

02

Market read

First‑report earnings and guidance update for a small‑cap healthcare company; potential catalyst for price movement.

03

What to watch

Potential regulatory changes and payer reimbursement pressure could curb future growth.

Relevance 7/10Novelty 8/10Timing: post-market today

Background

Viemed Healthcare, a NASDAQ‑listed home‑based health services provider, released its Q3 2026 results and updated full‑year guidance.

Company-level read

Ticker impact

$VMDBullishHigh confidence
Context

Viemed raised the low end of its 2026 revenue guidance to $316M and reported record Q3 revenue of $80.7M.

Expected impact

likely upside as investors price in higher revenue outlook

Evidence & confidence

The upward revision of revenue guidance and record quarterly results suggest improved operating performance, which typically supports a price rally.

Market effects

Home‑based healthcare providers may benefit from perceived demand growth.

U.S. healthcare stocks could see modest buying pressure.

Limited to U.S. small‑cap healthcare sector.

Counterpoint

Guidance may be optimistic given higher capital intensity and reimbursement risks.

Key entities

  • Viemed Healthcare, Inc.

    NASDAQ:VMD, provider of home‑based healthcare solutions.

  • Casey Hoyt

    CEO of Viemed who commented on the results.

Related articles

$VMDMedAI 8/10

Viemed Healthcare Q3 Earnings Call Highlights

VieMed Healthcare (VMD) reported Q3 operating cash flow of $11.5M and free cash flow of $4M. The company expects Q4 improvements in collections and active ventilator patients. Full-year revenue guidance was raised to $316M-$320M, while adjusted EBITDA was narrowed to $64M-$66M. VieMed had $9.7M in cash and $5.3M in borrowings at Q3's end, with a $1M share buyback and $2M term-loan repayment in October.

$VMDMed

Viemed Healthcare Inc (VMD) (Q3 2026) Earnings Call Highlights: Record Revenue

Viemed Healthcare reported Q3 2026 record revenue of $80M. CEO Casey Boyd discussed state rollout timelines, expecting gradual growth. CFO Trey Fitzgerald addressed sequential growth gaps, seasonal trends, and financial KPIs, targeting EBITDA above 20%. Accounts receivable delays impacted cash flow but are expected to resolve in Q4. Boyd also updated on sales force training, M&A pipeline, and patient education progress.

$VMDMed

VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (November 4, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, an

$VMDMedAI 8/10

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions

Med

Viemed Healthcare Announces New Share Repurchase Program of Up to 5% of Shares Outstanding – Minichart

Viemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.